SEC Form 4 · accession 0001179110-18-014176
INVIVO THERAPEUTICS HOLDINGS CORP. · NVIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard M. Toselli
Officer — See Remarks
Period of report
Dec 18, 2018
Accepted (ET)
Dec 20, 2018 · 3:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001292519
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 18, 2018 | A | 12,000 | $0.00 | A | 12,000 | D | |
| Common StockF2 | Dec 18, 2018 | F | 961 | $1.69 | D | 11,039 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F13,000 shares representing the one-for-one conversion of restricted stock units ("RSUs") vested on December 18, 2018. Subject to Dr. Toselli's continued employment with the Company, the remaining 9,000 shares will vest in equal monthly installments until fully vested on December 18, 2021.
- F2Represents shares sold by the reporting person pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2018 to satisfy tax withholding obligations applicable to the vesting of 3,000 stock-settled RSUs referenced in Footnote 1.
Remarks
President and Chief Executive Officer